Provided By PR Newswire
Last update: Sep 10, 2024
New Research Confirms the Benefit of Dario's Integrated, Data-Driven Approach to Health and Chronic Condition Management
NEW YORK, Sept. 10, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market announced today the publication of a new study in the peer-reviewed journal Frontiers in Endocrinology. The study demonstrates the effectiveness of Dario's cardiometabolic solution for members living with diabetes or prediabetes and depression.
Read more at prnewswire.comNASDAQ:DRIO (7/25/2025, 8:00:01 PM)
0.6512
-0.02 (-3.05%)
Find more stocks in the Stock Screener